A COVID-19 vaccine being developed by the University of Oxford in collaboration with AstraZeneca Plc is producing a similar immune response in both older and younger adults, signaling hopes that the vaccine could be a frontrunner among the numerous vaccines in production and testing.
Adverse responses were also lower among the elderly, adding more promise to the vaccine’s potential as a possible preventative measure against COVID-19.
The Oxford/AstraZeneca vaccine is expected to be one of the first from big pharma to secure regulatory approval, along with Pfizer and BioNTech’s candidate. Eric Sorensen reports.
For more info, please go to
Subscribe to Global News Channel HERE:
Like Global News on Facebook HERE:
Follow Global News on Twitter HERE:
Follow Global News on Instagram HERE:
#GlobalNews #COVID19 #coronavirus
